Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of Lutetium-177-PSMA-617 in metastatic prostate cancer after prostatectomy and orchiectomy
IRCT20230414057906N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Shahid Beheshti University of Medical Sciences. Started May 2023; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on IRCT20230414057906N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230414057906N1.